EyePoint Pharmaceuticals: Q4 Earnings Insights

Shares of EyePoint Pharmaceuticals EYPT moved lower by 2.5% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 9.09% year over year to ($0.10), which were in line with the estimate of ($0.10).

Revenue of $4,122,000 decreased by 42.83% from the same period last year, which beat the estimate of $3,730,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 05, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/jnqtvad7

Technicals

52-week high: $2.69

52-week low: $0.66

Price action over last quarter: down 13.34%

Company Overview

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed 5 FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.